Director/PDMR Shareholding
Hikma Pharmaceuticals PLC - EIP Awards
LONDON, 17 May 2018: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK)
(LEI: 549300BNS685UXH4JI75) announces that the Remuneration Committee has made the following conditional awards and nil cost option under the Hikma Pharmaceuticals PLC 2014 Executive Incentive Plan (the "EIP") to Persons Discharging Managerial Responsibility ("PDMR") of the Company.
Awards under the EIP were made on 16 May 2018 at a price of 1,035 pence per Ordinary Share (being the average price for the 30-day period prior to 31 December 2017, in accordance with the EIP rules) as follows:
Notification and public disclosure of transactions by persons discharging managerial responsibilities
Mazen Darwazah
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|
|
a) |
Name |
Mazen Darwazah |
|
2 |
Reason for the notification |
|
|
a) |
Position/status |
Executive Vice Chairman |
|
b) |
Initial notification /Amendment |
Initial notification |
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
|
a) |
Name |
Hikma Pharmaceuticals PLC |
|
b) |
LEI |
549300BNS685UXH4JI75 |
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
|
a) |
Description of the financial instrument, type of instrument and identification code |
Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
|
b) |
Nature of the transaction
|
The Company granted the named individual above a conditional award to acquire Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares under Element B EIP award will vest after 2 years |
|
c) |
Price(s) and volume(s) |
Price(s): £10.35 Volume(s): 16,953 |
|
d) |
Aggregated information |
N/A |
|
e) |
Date of the transaction |
16 May 2018 |
|
f) |
Place of the transaction |
London Stock Exchange (XLON) |
Mazen Darwazah
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|
|
a) |
Name |
Mazen Darwazah |
|
2 |
Reason for the notification |
|
|
a) |
Position/status |
Executive Vice Chairman |
|
b) |
Initial notification /Amendment |
Initial notification |
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
|
a) |
Name |
Hikma Pharmaceuticals PLC |
|
b) |
LEI |
549300BNS685UXH4JI75 |
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
|
a) |
Description of the financial instrument, type of instrument and identification code |
Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
|
b) |
Nature of the transaction
|
The Company granted the named individual above a conditional award to acquire Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares under Element C EIP award will vest after 3 years |
|
c) |
Price(s) and volume(s) |
Price(s): £10.35 Volume(s): 12,042 |
|
d) |
Aggregated information |
N/A |
|
e) |
Date of the transaction |
16 May 2018 |
|
f) |
Place of the transaction |
London Stock Exchange (XLON) |
Bassam Kanaan
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|
|
a) |
Name |
Bassam Kanaan |
|
2 |
Reason for the notification |
|
|
a) |
Position/status |
Chief Strategy and Corporate Development Officer |
|
b) |
Initial notification /Amendment |
Initial notification |
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
|
a) |
Name |
Hikma Pharmaceuticals PLC |
|
b) |
LEI |
549300BNS685UXH4JI75 |
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
|
a) |
Description of the financial instrument, type of instrument and identification code |
Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
|
b) |
Nature of the transaction
|
The Company granted the named individual above a conditional award to acquire Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares under Element B EIP award will vest after 2 years |
|
c) |
Price(s) and volume(s) |
Price(s): £10.35 Volume(s): 25,729 |
|
d) |
Aggregated information |
N/A |
|
e) |
Date of the transaction |
16 May 2018 |
|
f) |
Place of the transaction |
London Stock Exchange (XLON) |
Bassam Kanaan
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|
|
a) |
Name |
Bassam Kanaan |
|
2 |
Reason for the notification |
|
|
a) |
Position/status |
Chief Strategy and Corporate Development Officer |
|
b) |
Initial notification /Amendment |
Initial notification |
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
|
a) |
Name |
Hikma Pharmaceuticals PLC |
|
b) |
LEI |
549300BNS685UXH4JI75 |
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
|
a) |
Description of the financial instrument, type of instrument and identification code |
Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
|
b) |
Nature of the transaction
|
The Company granted the named individual above a conditional award to acquire Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares under Element C EIP award will vest after 3 years |
|
c) |
Price(s) and volume(s) |
Price(s): £10.35 Volume(s): 25,729 |
|
d) |
Aggregated information |
N/A |
|
e) |
Date of the transaction |
16 May 2018 |
|
f) |
Place of the transaction |
London Stock Exchange (XLON) |
Khalid Nabilsi
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|
|
a) |
Name |
Khalid Nabilsi |
|
2 |
Reason for the notification |
|
|
a) |
Position/status |
Chief Financial Officer |
|
b) |
Initial notification /Amendment |
Initial notification |
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
|
a) |
Name |
Hikma Pharmaceuticals PLC |
|
b) |
LEI |
549300BNS685UXH4JI75 |
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
|
a) |
Description of the financial instrument, type of instrument and identification code |
Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
|
b) |
Nature of the transaction
|
The Company granted the named individual above a conditional award to acquire Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares under Element B EIP award will vest after 2 years |
|
c) |
Price(s) and volume(s) |
Price(s): £10.35 Volume(s): 23,062 |
|
d) |
Aggregated information |
N/A |
|
e) |
Date of the transaction |
16 May 2018 |
|
f) |
Place of the transaction |
London Stock Exchange (XLON) |
Khalid Nabilsi
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|
|
a) |
Name |
Khalid Nabilsi |
|
2 |
Reason for the notification |
|
|
a) |
Position/status |
Chief Financial Officer |
|
b) |
Initial notification /Amendment |
Initial notification |
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
|
a) |
Name |
Hikma Pharmaceuticals PLC |
|
b) |
LEI |
549300BNS685UXH4JI75 |
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
|
a) |
Description of the financial instrument, type of instrument and identification code |
Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
|
b) |
Nature of the transaction
|
The Company granted the named individual above a conditional award to acquire Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares under Element C EIP award will vest after 3 years |
|
c) |
Price(s) and volume(s) |
Price(s): £10.35 Volume(s): 23,062 |
|
d) |
Aggregated information |
N/A |
|
e) |
Date of the transaction |
16 May 2018 |
|
f) |
Place of the transaction |
London Stock Exchange (XLON) |
Riad Mishlawi
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|
|
a) |
Name |
Riad Mishlawi |
|
2 |
Reason for the notification |
|
|
a) |
Position/status |
CEO, Injectables Division |
|
b) |
Initial notification /Amendment |
Initial notification |
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
|
a) |
Name |
Hikma Pharmaceuticals PLC |
|
b) |
LEI |
549300BNS685UXH4JI75 |
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
|
a) |
Description of the financial instrument, type of instrument and identification code |
Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
|
b) |
Nature of the transaction
|
The Company granted the named individual above a conditional award to acquire Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares under Element B EIP award will vest after 2 years |
|
c) |
Price(s) and volume(s) |
Price(s): £10.35 Volume(s): 22,601 |
|
d) |
Aggregated information |
N/A |
|
e) |
Date of the transaction |
16 May 2018 |
|
f) |
Place of the transaction |
London Stock Exchange (XLON) |
Riad Mishlawi
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|
|
a) |
Name |
Riad Mishlawi |
|
2 |
Reason for the notification |
|
|
a) |
Position/status |
CEO, Injectables Division |
|
b) |
Initial notification /Amendment |
Initial notification |
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
|
a) |
Name |
Hikma Pharmaceuticals PLC |
|
b) |
LEI |
549300BNS685UXH4JI75 |
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
|
a) |
Description of the financial instrument, type of instrument and identification code |
Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
|
b) |
Nature of the transaction
|
The Company granted the named individual above a conditional award to acquire Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares under Element C EIP award will vest after 3 years |
|
c) |
Price(s) and volume(s) |
Price(s): £10.35 Volume(s): 22,601 |
|
d) |
Aggregated information |
N/A |
|
e) |
Date of the transaction |
16 May 2018 |
|
f) |
Place of the transaction |
London Stock Exchange (XLON) |
Majda Labadi
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|
|
a) |
Name |
Majda Labadi |
|
2 |
Reason for the notification |
|
|
a) |
Position/status |
Chief Human Capital Officer |
|
b) |
Initial notification /Amendment |
Initial notification |
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
|
a) |
Name |
Hikma Pharmaceuticals PLC |
|
b) |
LEI |
549300BNS685UXH4JI75 |
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
|
a) |
Description of the financial instrument, type of instrument and identification code |
Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
|
b) |
Nature of the transaction
|
The Company granted the named individual above a conditional award to acquire Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares under Element B EIP award will vest after 2 years |
|
c) |
Price(s) and volume(s) |
Price(s): £10.35 Volume(s): 15,855 |
|
d) |
Aggregated information |
N/A |
|
e) |
Date of the transaction |
16 May 2018 |
|
f) |
Place of the transaction |
London Stock Exchange (XLON) |
Majda Labadi
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|
|
a) |
Name |
Majda Labadi |
|
2 |
Reason for the notification |
|
|
a) |
Position/status |
Chief Human Capital Officer |
|
b) |
Initial notification /Amendment |
Initial notification |
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
|
a) |
Name |
Hikma Pharmaceuticals PLC |
|
b) |
LEI |
549300BNS685UXH4JI75 |
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
|
a) |
Description of the financial instrument, type of instrument and identification code |
Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
|
b) |
Nature of the transaction
|
The Company granted the named individual above a conditional award to acquire Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares under Element C EIP award will vest after 3 years |
|
c) |
Price(s) and volume(s) |
Price(s): £10.35 Volume(s): 15,855 |
|
d) |
Aggregated information |
N/A |
|
e) |
Date of the transaction |
16 May 2018 |
|
f) |
Place of the transaction |
London Stock Exchange (XLON) |
Susan Ringdal
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|
|
a) |
Name |
Susan Ringdal |
|
2 |
Reason for the notification |
|
|
a) |
Position/status |
Vice President, Corporate Strategy and Investor Relations |
|
b) |
Initial notification /Amendment |
Initial notification |
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
|
a) |
Name |
Hikma Pharmaceuticals PLC |
|
b) |
LEI |
549300BNS685UXH4JI75 |
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
|
a) |
Description of the financial instrument, type of instrument and identification code |
Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
|
b) |
Nature of the transaction
|
The Company granted the named individual above a conditional award to acquire Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares under Element B EIP award will vest after 2 years |
|
c) |
Price(s) and volume(s) |
Price(s): £10.35 Volume(s): 14,257 |
|
d) |
Aggregated information |
N/A |
|
e) |
Date of the transaction |
16 May 2018 |
|
f) |
Place of the transaction |
London Stock Exchange (XLON) |
Susan Ringdal
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|
|
a) |
Name |
Susan Ringdal |
|
2 |
Reason for the notification |
|
|
a) |
Position/status |
Vice President, Corporate Strategy and Investor Relations |
|
b) |
Initial notification /Amendment |
Initial notification |
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
|
a) |
Name |
Hikma Pharmaceuticals PLC |
|
b) |
LEI |
549300BNS685UXH4JI75 |
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
|
a) |
Description of the financial instrument, type of instrument and identification code |
Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
|
b) |
Nature of the transaction
|
The Company granted the named individual above a conditional award to acquire Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares under Element C EIP award will vest after 3 years |
|
c) |
Price(s) and volume(s) |
Price(s): £10.35 Volume(s): 14,257 |
|
d) |
Aggregated information |
N/A |
|
e) |
Date of the transaction |
16 May 2018 |
|
f) |
Place of the transaction |
London Stock Exchange (XLON) |
Brian Hoffman
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|
|
a) |
Name |
Brian Hoffmann |
|
2 |
Reason for the notification |
|
|
a) |
Position/status |
President, US Generics Division |
|
b) |
Initial notification /Amendment |
Initial notification |
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
|
a) |
Name |
Hikma Pharmaceuticals PLC |
|
b) |
LEI |
549300BNS685UXH4JI75 |
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
|
a) |
Description of the financial instrument, type of instrument and identification code |
Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
|
b) |
Nature of the transaction
|
The Company granted the named individual above a conditional award to acquire Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares under Element B EIP award will vest after 2 years |
|
c) |
Price(s) and volume(s) |
Price(s): £10.35 Volume(s): 18,247 |
|
d) |
Aggregated information |
N/A |
|
e) |
Date of the transaction |
16 May 2018 |
|
f) |
Place of the transaction |
London Stock Exchange (XLON) |
Bryan Hotston
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|
|
a) |
Name |
Bryan Hotston |
|
2 |
Reason for the notification |
|
|
a) |
Position/status |
Chief Information Officer |
|
b) |
Initial notification /Amendment |
Initial notification |
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
|
a) |
Name |
Hikma Pharmaceuticals PLC |
|
b) |
LEI |
549300BNS685UXH4JI75 |
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
|
a) |
Description of the financial instrument, type of instrument and identification code |
Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
|
b) |
Nature of the transaction
|
The Company granted the named individual above a conditional award to acquire Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares under Element B EIP award will vest after 2 years |
|
c) |
Price(s) and volume(s) |
Price(s): £10.35 Volume(s): 17,016 |
|
d) |
Aggregated information |
N/A |
|
e) |
Date of the transaction |
16 May 2018 |
|
f) |
Place of the transaction |
London Stock Exchange (XLON) |
Hussein Arkhagha
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|
|
a) |
Name |
Hussein Arkhagha |
|
2 |
Reason for the notification |
|
|
a) |
Position/status |
General Counsel |
|
b) |
Initial notification /Amendment |
Initial notification |
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
|
a) |
Name |
Hikma Pharmaceuticals PLC |
|
b) |
LEI |
549300BNS685UXH4JI75 |
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
|
a) |
Description of the financial instrument, type of instrument and identification code |
Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
|
b) |
Nature of the transaction
|
The Company granted the named individual above a conditional award to acquire Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares under Element B EIP award will vest after 2 years |
|
c) |
Price(s) and volume(s) |
Price(s): £10.35 Volume(s): 13,489 |
|
d) |
Aggregated information |
N/A |
|
e) |
Date of the transaction |
16 May 2018 |
|
f) |
Place of the transaction |
London Stock Exchange (XLON) |
Peter Speirs
Company Secretary, responsible for releasing this announcement
+44 (0) 20 7399 2760
This information is provided by RNS
COMPANIES COVERED:
Latest directors dealings
- 2 days ago FRP Advisory Group
- 2 days ago Marks Electrical Group
- 2 days ago CLS Holdings
- 2 days ago QinetiQ Group
- 2 days ago Spectris